<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19878">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01734811</url>
  </required_header>
  <id_info>
    <org_study_id>MV130-SLG-002</org_study_id>
    <secondary_id>2012-002450-24</secondary_id>
    <nct_id>NCT01734811</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation in Recurrent Bronchospasms</brief_title>
  <acronym>MV130</acronym>
  <official_title>Randomized Double-blind Placebo-controlled, Parallel, Single Centre Clinical Trial of Sublingual Bacterial Vaccine in Children With Recurrent Bronchospasm for the Evaluation of Efficacy, Security and Clinical Impact.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unidad de Investigacion Medica en Epidemiologia Clinica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inmunotek S.L.</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of a biological vaccine to prevent
      episodes of bronchospasm, induced by recurrent respiratory tract infections, in children,
      compared with a placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind parallel placebo controlled study. The subjects will receive medication during
      6 months and will be followed up during another six months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Recurrent bronchospasm</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction in the number of bronchospasms episodes compared with previous year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shortening of the severity of the bronchospasm episodes</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication consumption</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct costs</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Counting the: unscheduled visits to health center, emergency service visits, days of hospitalization and cost thereof, complementary tests, phone calls to the doctor or pediatrician per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect costs</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Counting the: absenteeism from nursery, caregivers to the child at home and during hospital admissions per patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Bronchospasm</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will receive daily dose of the biological vaccine during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biological vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive daily dose of the biological vaccine during 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological vaccine</intervention_name>
    <description>Daily dose</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Biological vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects whose parents /legal representative have given written informed consent.

          -  Both gender

          -  Subject up to 36 months of age.

          -  Subjects with recurrent bronchospasms ; 3 or more exacerbations in the last 12 months

        Exclusion Criteria:

          -  Subjects whose parents/legal representative have not given written informed consent.

          -  Subjects out of aged range

          -  Subjects with malignancies or chemotherapy treatment

          -  Subjects included in another clinical trial in the last 12 months.

          -  Subject in immunosuppressive or immunostimulatory treatment

          -  Subjects who have received iv gamma globulin in the past 12 months.

          -  Subjects diagnosed with candidiasis or fungal recurrent infections.

          -  Subjects diagnosed with malabsorption syndrome

          -  Subjects with clinical allergy to common aeroallergens in the geographical area.

          -  Subjects with hepatitis virus infections, HIV and tuberculosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Casanovas, PhD; MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Nieto, PhD; MD</last_name>
    <phone>34961244378</phone>
    <email>nieto_ant@gva.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel Casanovas, PhD; MD</last_name>
    <phone>34916510010</phone>
    <email>mcasanovas@inmunotek.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Nieto, PhD; MD</last_name>
      <phone>34961244378</phone>
      <email>nieto_ant@gva.es</email>
    </contact>
    <contact_backup>
      <last_name>Miguel Casanovas, PhD; MD</last_name>
      <phone>34916510010</phone>
      <email>mcasanovas@inmunotek.com</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Nieto, PhD; MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>November 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Bronchospasm</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchial Spasm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
